Immunomedics is a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune diseases, and other serious diseases. The company also has a majority ownership in IBC Pharmaceuticals, which is developing a novel DOCK-AND-LOCK method for making fusion proteins and multifunctional antibodies.
The company reported today that IBC Pharmaceuticals has received notice that its patent application for “Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases” will be issued U.S. patent no. 8,349,332 today. The patent will provide coverage until 2026.
The patent concerns methods of use of hexavalent DOCK-AND-LOCK constructs, comprising antibodies and/or antigen-binding antibody fragements tethered together using IBC’s patented platform technology. The bispecific antibodies bind to CD20 and CD22 antigens on B-cells. The complexes are used in treatment of B-cell malignancies or B-cell-related autoimmune diseases.
Immunomedics previously reported potent anti-tumor activity of a new class of hexavalent bispecific antibodies targeting CD20 and CD22 in an animal model of human non-Hodgkin lymphoma. These complexes extended the median survival time of animals in a statistically significant manner.
For additional information about Immunomedics, please visit www.immunomedics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
